A new study led by researchers at the MRC Molecular Haematology Unit has shown that resistance to a targeted treatment for acute myeloid leukaemia (AML) can develop much earlier than expected.
RDM scientists have achieved the most detailed view yet of how DNA folds and functions inside living cells, revealing the physical structures that control when and how genes are switched on.
Congratulations are in order for Dr Abdullah (Abs) Khan, who has been awarded a Wellcome Career Development Award for his research on age-related immune dysfunction using human model systems.
Oxford scientists build a connected, \u2018multi-organoid\u2019 platform that recreates immune recruitment to the heart, opening new avenues to probe disease and test therapies.
Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for infants and children with high-risk leukaemia.
The foundation has awarded one of its first major research grants to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group in the MRC Molecular Haematology Unit.
Earlier this year, a group of researchers from the MRC Weatherall Institute of Molecular Medicine attended the Big Bang Fair in Birmingham, showcasing medical research through a series of hands-on activities.
Study led by Psaila Group uncovers previously unknown function of platelets as DNA \u2018vacuum cleaners\u2019 in the blood, with profound implications for cancer diagnosis and prenatal screening.
Claus Nerlov, Professor of Stem Cell Biology, has been awarded funding from Wellcome to map the gene regulatory networks in blood cell production and seek new therapeutic targets.
Researchers at the MRC Weatherall Institute of Molecular Medicine and the German Cancer Research Center (DKFZ) have developed a new method to analyse how our tissues evolve as we age.
The MRC WIMM community gathered for its flagship annual event, WIMM Day, on Tuesday 24th June. Held at the Sa\u00efd Business School, the day showcased the breadth and impact of research across the institute and celebrated achievements in mentorship, public engagement and more.
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
Professor Adam Mead is Editor-in-Chief and Graham Collins and Deborah Hay two of the editors for the eighth edition of this key reference work, now in its sixth decade.
Associate Professor Adam Wilkinson has received the 2025 Janet Rowley Award from the International Society for Experimental Haematology for his outstanding contributions in the field of hematopoietic stem cell biology.
![\"Patient](\"https://www.imm.ox.ac.uk/news/drug-resistance-targeted-aml-therapy/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n